501 related articles for article (PubMed ID: 26045776)
21. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
23. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
24. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
25. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
27. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
28. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW
Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer.
Zou W; Ma X; Yang H; Hua W; Chen B; Cai G
Exp Biol Med (Maywood); 2017 Mar; 242(5):497-504. PubMed ID: 28056551
[TBL] [Abstract][Full Text] [Related]
32. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
33. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.
Wu W; Yu LH; Ma B; Xu MJ
PLoS One; 2014; 9(3):e89841. PubMed ID: 24598933
[TBL] [Abstract][Full Text] [Related]
34. MACC1 mediates chemotherapy sensitivity of 5-FU and cisplatin via regulating MCT1 expression in gastric cancer.
Wang C; Wen Z; Xie J; Zhao Y; Zhao L; Zhang S; Liu Y; Xue Y; Shi M
Biochem Biophys Res Commun; 2017 Apr; 485(3):665-671. PubMed ID: 28235486
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
[TBL] [Abstract][Full Text] [Related]
36. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
Bratasz A; Selvendiran K; Wasowicz T; Bobko A; Khramtsov VV; Ignarro LJ; Kuppusamy P
J Transl Med; 2008 Feb; 6():9. PubMed ID: 18302761
[TBL] [Abstract][Full Text] [Related]
37. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
[TBL] [Abstract][Full Text] [Related]
38. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
Qin S; Li Y; Cao X; Du J; Huang X
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
[TBL] [Abstract][Full Text] [Related]
39. Chloroquine reverses chemoresistance via upregulation of p21
Hwang JR; Kim WY; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim MS; Kim JH; Paik ES; Lee YY; Han HD; Lee JW
Cell Death Dis; 2020 Dec; 11(12):1034. PubMed ID: 33277461
[TBL] [Abstract][Full Text] [Related]
40. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]